Twist and Shout: One Decade of Meta-Analyses of Erythropoiesis-Stimulating Agents in Cancer Patients

By  

Acta Haematologica, Vol. 125, Iss. 1-2, 2010-12 ,pp. : 55-67

Karger

Access to resources Recommend Favorite

The Effect of Erythropoiesis-Stimulating Agents in Patients with Therapy-Refractory Autoimmune Hemolytic Anemia

By  

Transfusion Medicine and Hemotherapy, Vol. 41, Iss. 6, 2014-09 ,pp. : 462-468

Karger

Access to resources Recommend Favorite

Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis‐stimulating agents and transfusion in patients with chemotherapy‐induced anaemia

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 40, Iss. 3, 2015-06 ,pp. : 299-303

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents*

By Silver M. R.   Geronemus R.   Krause M.   Chen C. Y.   Kewalramani R.   Stehman-Breen C.  

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 123-131

Informa Healthcare

Access to resources Recommend Favorite

Complete correction of anemia by erythropoiesis-stimulating agents is associated with insulin resistance in hemodialysis patients

By Biolo Gianni   Guarnieri Gianfranco   Barazzoni Rocco   Panzetta Giovanni  

Clinical and Experimental Medicine, Vol. 11, Iss. 3, 2011-09 ,pp. : 181-187

Springer Publishing Company

Access to resources Recommend Favorite